Achilleas Fardellas

Mr. Achilleas Fardellas

AstraZeneca
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2020 in Cells
Verified
Journal Article
Open access
PDF file
THTracey Hurrell
Tracey Hurrell
VKVlasia Kastrinou-Lampou
Vlasia Kastrinou-Lampou
Achilleas FardellasAchilleas Fardellas
Achilleas Fardellas
DHDelilah F. G. Hendriks
Delilah F. G. Hendriks
ÅNÅsa Nordling
Åsa Nordling
MIMagnus Ingelman-Sundberg
Magnus Ingelman-Sundberg
Non-alcoholic fatty liver disease affects approximately one billion adults worldwide. Non-alcoholic steatohepatitis (NASH) is a progressive disease and underlies the advancement to liver fibrosis, cirrhosis, and hepatocellular carcinoma, for which there are no FDA-approved drug therapies. We developed a hetero-cellular spheroid system comprised of primary human hepatocytes (PHH) co-cultured with crude fractions of primary human liver non-parenchymal cells (NPC) from several matched or non-matched donors, to identify phenotypes with utility in investigating NASH pathogenesis and drug screening. Co-culture spheroids displayed stable expression of hepatocyte markers (albumin, CYP3A4) with the integration of stellate (vimentin, PDGFRβ), endothelial (vWF, PECAM1), and CD68-positive cells. Several co-culture spheroids developed a fibrotic phenotype either spontaneously, primarily observed in PNPLA3 mutant donors, or after challenge with free fatty acids (FFA), as determined by COL1A1 and αSMA expression. This phenotype, as well as TGFβ1 expression, was attenuated with an ALK5 inhibitor. Furthermore, CYP2E1, which has a strong pro-oxidant effect, was induced by NPCs and FFA. This system was used to evaluate the effects of anti-NASH drug candidates, which inhibited fibrillary deposition following 7 days of exposure. In conclusion, we suggest that this system is suitable for the evaluation of NASH pathogenesis and screening of anti-NASH drug candidates.

6 July 2023 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
EBEmelie Barreby
Emelie Barreby
BSBenedikt Strunz
Benedikt Strunz
SNSebastian Nock
Sebastian Nock
LNLéa Naudet
Léa Naudet
JSJoanne X. Shen
Joanne X. Shen
MAMyriam Aouadi
Myriam Aouadi
Although multiple populations of macrophages have been described in the human liver, their function and turnover in patients with obesity at high risk of developing non-alcoholic fatty liver disease (NAFLD) and cirrhosis are currently unknown. Herein, we identify a specific human population of resident liver myeloid cells that protects against the metabolic impairment associated with obesity. By studying the turnover of liver myeloid cells in individuals undergoing liver transplantation, we find that liver myeloid cell turnover differs between humans and mice. Using single-cell techniques and flow cytometry, we determine that the proportion of the protective resident liver myeloid cells, denoted liver myeloid cells 2 (LM2), decreases during obesity. Functional validation approaches using human 2D and 3D cultures reveal that the presence of LM2 ameliorates the oxidative stress associated with obese conditions. Our study indicates that resident myeloid cells could be a therapeutic target to decrease the oxidative stress associated with NAFLD.

24 September 2022 in Annales d'Endocrinologie
Verified
Journal Article
Closed access
ADA. Dumond
A. Dumond
JPJ.B. Potier
J.B. Potier
Achilleas FardellasAchilleas Fardellas
Achilleas Fardellas
MAM. Aouadi
M. Aouadi
KBK. Bouzakri
K. Bouzakri